
Sanjay K Agarwal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6246237/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical diagnosis of endometriosis: a call to action. American Journal of Obstetrics and Gynecology, 2019, 220, 354.e1-354.e12.	0.7	362
2	Alcohol, drugs, caffeine, tobacco, and environmental contaminant exposure: Reproductive health consequences and clinical implications. Critical Reviews in Toxicology, 2010, 40, 633-652.	1.9	97
3	Long-Term Outcomes of Elagolix in Women With Endometriosis. Obstetrics and Gynecology, 2018, 132, 147-160.	1.2	91
4	Impact of Endometriosis on Life-Course Potential: A Narrative Review. International Journal of General Medicine, 2021, Volume 14, 9-25.	0.8	75
5	The effects of dietary phytoestrogens on aromatase activity in human endometrial stromal cells. Reproduction, Nutrition, Development, 2005, 45, 709-720.	1.9	51
6	Assessing brain-derived neurotrophic factor as a novel clinical marker of endometriosis. Fertility and Sterility, 2016, 105, 119-128.e5.	0.5	50
7	Endometriosis-associated infertility. Current Opinion in Obstetrics and Gynecology, 2000, 12, 377-381.	0.9	36
8	<p>Rethinking endometriosis care: applying the chronic care model via a multidisciplinary program for the care of women with endometriosis</p> . International Journal of Women's Health, 2019, Volume 11, 405-410.	1.1	34
9	MicroRNA expression pattern differs depending on endometriosis lesion typeâ€. Biology of Reproduction, 2018, 98, 623-633.	1.2	33
10	Estrogen induced changes in uterine brain-derived neurotrophic factor and its receptors. Human Reproduction, 2015, 30, 925-936.	0.4	30
11	Appendiceal Disease in Women with Endometriosis and Right Lower Quadrant Pain. Journal of Minimally Invasive Gynecology, 2001, 8, 536-541.	1.4	28
12	Reduction in Endometrioma Size with Three Months of Aromatase Inhibition and Progestin Add-Back. BioMed Research International, 2015, 2015, 1-4.	0.9	25
13	Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. Fertility and Sterility, 2019, 112, 298-304.e3.	0.5	24
14	Endometrial microbiota is more diverse in people with endometriosis than symptomatic controls. Scientific Reports, 2021, 11, 18877.	1.6	24
15	Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone. BioMed Research International, 2015, 2015, 1-9.	0.9	20
16	Health Care Utilization and Costs Associated with Endometriosis Among Women with Medicaid Insurance. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 566-572.	0.5	20
17	Environmental Contaminants and Dietary Factors in Endometriosis. Annals of the New York Academy of Sciences, 2002, 955, 213-229.	1.8	19
18	The Impact of Endometriosis across the Lifespan of Women: Foreseeable Research and Therapeutic Prospects. BioMed Research International, 2015, 2015, 1-8.	0.9	19

SANJAY K AGARWAL

#	Article	IF	CITATIONS
19	Real-world characteristics of women with endometriosis-related pain entering a multidisciplinary endometriosis program. BMC Women's Health, 2021, 21, 19.	0.8	16
20	Cost–effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA. Journal of Comparative Effectiveness Research, 2019, 8, 337-355.	0.6	12
21	WHAT MOTIVATES WOMEN TO TAKE PART IN CLINICAL AND BASIC SCIENCE ENDOMETRIOSIS RESEARCH?. Bioethics, 2007, 21, 263-269.	0.7	9
22	Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials. Patient, 2019, 12, 651-660.	1.1	9
23	Impact of six months of GnRH agonist therapy for endometriosis. Is there an age-related effect on bone mineral density?. Journal of reproductive medicine, The, 2002, 47, 530-4.	0.2	9
24	Predictors of treatment failure in young patients undergoing in vitro fertilization. Journal of Assisted Reproduction and Genetics, 2016, 33, 1001-1007.	1.2	8
25	Factors affecting stability of plasma brain-derived neurotrophic factor. Scientific Reports, 2020, 10, 20232.	1.6	8
26	<p>Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database</p> . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 473-479.	0.7	7
27	Application of the Estrogen Threshold Hypothesis to the Physiologic Hypoestrogenemia of Lactation. Breastfeeding Medicine, 2015, 10, 77-83.	0.8	6
28	Development of the Painful Periods Screening Tool for endometriosis. Postgraduate Medicine, 2018, 130, 694-702.	0.9	5
29	Elagolix in the treatment of endometriosis: impact beyond pain symptoms. Therapeutic Advances in Reproductive Health, 2020, 14, 263349412096451.	1.3	5
30	Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix. Journal of Pain Research, 2021, Volume 14, 263-271.	0.8	5
31	A critical appraisal of the circulating levels of differentially expressed microRNA in endometriosis. Biology of Reproduction, 2021, 105, 1075-1085.	1.2	5
32	Psychometric assessment of the health-related productivity questionnaire (HRPQ) among women with endometriosis. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 531-539.	0.7	4
33	Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 21, 1-9.	0.7	3
34	The Impact of Endometriosis on the Health of Women. BioMed Research International, 2015, 2015, 1-1.	0.9	2
35	National Patterns of Emergency Department Use for Women with Endometriosis, 2006–2015. Journal of Women's Health, 2020, 29, 420-426.	1.5	2
36	Reply. American Journal of Obstetrics and Gynecology, 2019, 221, 171.	0.7	1

#	Article	IF	CITATIONS
37	microRNA and Overcoming the Challenges of Their Use in the Diagnosis of Endometriosis. , 0, , .		0